James B. Couch, M.D., J.D., director-in-charge of disease management for Coopers & Lybrand Integrated Healthcare Consulting, has published his second book, "The Physician's Guide to Disease Management." However, the comprehensive guide to disease management's initiatives, strategies and trends is not intended only for physicians. Representatives may read it to strengthen their understanding of this popular trend in managed health care.
James B. Couch, M.D., J.D., director-in-charge of disease management for Coopers & Lybrand Integrated Healthcare Consulting, has published his second book, "The Physician's Guide to Disease Management." However, the comprehensive guide to disease management's initiatives, strategies and trends is not intended only for physicians. Representatives may read it to strengthen their understanding of this popular trend in managed health care.
Pharmaceutical Representative: Why is a guide to disease management needed today?
Couch: There are so many misconceptions about what disease or health management is. Every group that has tried to define disease management in one way or another has had a different spin on it. Consequently, we need a book that can tie all the different perspectives together. We need to establish a common framework for what disease management is, as well as what it isn't.
Pharmaceutical Representative: Which diseases are the targets of the different programs?
Couch: Diabetes is one of the diseases and the book discusses how those patients were managed. Prenatal care, asthma and hypertension are also covered.
Pharmaceutical Representative: How can a pharmaceutical representative use your book?
Couch: The entire book is useful for salespeople who are in the business of calling on physicians to help them prescribe the best medicines.
One chapter specifically covers disease management in pharmaceutical companies. Others focus on evidence-based medicine, outcomes-validated clinical practice guidelines and examples of successfully implemented disease management programs.
These chapters would be relevant and interesting to a pharmaceutical representative. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.